Oragenics Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Oragenics has been growing earnings at an average annual rate of 4.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 39.8% per year.
Wichtige Informationen
4.5%
Wachstumsrate der Gewinne
36.2%
EPS-Wachstumsrate
Biotechs Wachstum der Industrie | 17.0% |
Wachstumsrate der Einnahmen | 39.8% |
Eigenkapitalrendite | -1,471.4% |
Netto-Marge | -261,401.5% |
Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Aufschlüsselung der Einnahmen und Ausgaben
Wie Oragenics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Jun 24 | 0 | -20 | 6 | 0 |
31 Mar 24 | 0 | -20 | 6 | 0 |
31 Dec 23 | 0 | -21 | 5 | 0 |
30 Sep 23 | 0 | -10 | 5 | 0 |
30 Jun 23 | 0 | -12 | 4 | 0 |
31 Mar 23 | 0 | -13 | 4 | 0 |
31 Dec 22 | 0 | -14 | 4 | 0 |
30 Sep 22 | 0 | -14 | 5 | 0 |
30 Jun 22 | 0 | -15 | 4 | 0 |
31 Mar 22 | 0 | -15 | 5 | 0 |
31 Dec 21 | 0 | -16 | 5 | 0 |
30 Sep 21 | 0 | -18 | 5 | -19 |
30 Jun 21 | 0 | -18 | 6 | -15 |
31 Mar 21 | 0 | -26 | 5 | -4 |
31 Dec 20 | 0 | -26 | 5 | 0 |
30 Sep 20 | 0 | -26 | 4 | 22 |
30 Jun 20 | 0 | -25 | 4 | 21 |
31 Mar 20 | 0 | -17 | 4 | 13 |
31 Dec 19 | 0 | -16 | 4 | 12 |
30 Sep 19 | 0 | -15 | 4 | 11 |
30 Jun 19 | 0 | -15 | 4 | 10 |
31 Mar 19 | 0 | -13 | 4 | 7 |
31 Dec 18 | 0 | -11 | 4 | 6 |
30 Sep 18 | 0 | -10 | 4 | 5 |
30 Jun 18 | 0 | -8 | 3 | 4 |
31 Mar 18 | 0 | -7 | 3 | 4 |
31 Dec 17 | 0 | -7 | 3 | 4 |
30 Sep 17 | 0 | -8 | 4 | 5 |
30 Jun 17 | 0 | -8 | 4 | 4 |
31 Mar 17 | 0 | -8 | 4 | 5 |
31 Dec 16 | 0 | -8 | 4 | 5 |
30 Sep 16 | 0 | -8 | 4 | 4 |
30 Jun 16 | 0 | -8 | 3 | 4 |
31 Mar 16 | 0 | -13 | 3 | 9 |
31 Dec 15 | 0 | -12 | 3 | 9 |
30 Sep 15 | 0 | -11 | 3 | 8 |
30 Jun 15 | 0 | -10 | 3 | 7 |
31 Mar 15 | 1 | -5 | 3 | 3 |
31 Dec 14 | 1 | -6 | 3 | 3 |
30 Sep 14 | 1 | -8 | 5 | 10 |
30 Jun 14 | 1 | -16 | 7 | 10 |
31 Mar 14 | 1 | -16 | 7 | 10 |
31 Dec 13 | 1 | -16 | 8 | 9 |
Qualität der Erträge: OGEN is currently unprofitable.
Wachsende Gewinnspanne: OGEN is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: OGEN is unprofitable, but has reduced losses over the past 5 years at a rate of 4.5% per year.
Beschleunigtes Wachstum: Unable to compare OGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: OGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: OGEN has a negative Return on Equity (-1471.37%), as it is currently unprofitable.